Juvenescence, a UK-based clinical-stage biotech founded in 2016, develops AI-enabled therapeutics for age-related disease and healthy lifespan. It closed a $76 million first tranche of its Series B-1 round, led by Abu Dhabi's M42, in May 2025.
At a glance
| Price from | Custom |
| Best for | Partners in age-related disease drug development |
From Juvenescence's own website.
What stands out
- Clinical-stage pipeline
- Strategic backing from M42
Worth knowing
- Older than most startups here
- Full round size not confirmed
How it ranks
Juvenescence is ranked 7th of 10 in Best Longevity Startups (Lister Score 89.1).
#7 in Best Longevity Startups · Lister Score 89.1
Juvenescence's M42 investment came with a strategic partnership to build a drug development hub in Abu Dhabi..
| Rank | Best Longevity Startups | Score |
|---|---|---|
| 1 | Altos Labs | 96.8 |
| 2 | NewLimit | 95.6 |
| 3 | Retro Biosciences | 94.3 |
| 4 | Loyal | 93.1 |
| 5 | Function Health | 91.8 |
| 6 | Life Biosciences | 90.4 |
| 7 | Juvenescence | 89.1 |
| 8 | Rubedo Life Sciences | 87.7 |
| 9 | Cambrian Bio | 86.4 |
| 10 | Gameto | 85.0 |
Frequently asked questions
How does Juvenescence rank on Lister?
Juvenescence is ranked 7th of 10 in Best Longevity Startups (Lister Score 89.1).
Appears in
Add this badge to your site
If you work at Juvenescence, paste this code into your website to show where it ranks on Lister. The badge links to the ranking and updates within a day when the rank changes.